Gilead Sciences (GILD) 108.13 $GILD
Gilead Sciences Is Shrugging Off Its Competitors
Todd Campbell, The Motley Fool - Motley Fool - Sat Oct 31, 6:20AM CDT
Image source: Gilead Sciences. The fact that Gilead Sciences shares have toppled by 8% since July might have you thinking that competitors have the company on the ropes, but Gilead Sciences' third-quarter results show investors that simply isn't...
GILD: 108.13 (-1.08), MRK: 54.66 (-0.21), ABBV: 59.55 (+5.45)
Gilead Sciences and WuXi PharmaTech Announce Collaboration for a Dedicated Analytical and Stability Testing Facility
PR Newswire - Thu Oct 29, 9:00PM CDT
Gilead Sciences, Inc., and WuXi PharmaTech (Cayman) Inc. (NYSE: WX), today announced that they have entered into a strategic partnership to conduct analytical and stability studies of small-molecule new chemical entities to support global marketing applications and commercial products.
GILD: 108.13 (-1.08), WX: 44.70 (+0.10)
Jim Cramer's 'Mad Money' Recap: Using What Went Wrong to Find Buying Opportunities
at The Street - Thu Oct 29, 7:16PM CDT
One company's awful earnings can drag others down in the sector, making bargains for the taking, Cramer syas.
HON: 103.28 (+0.34), PYPL: 36.01 (+0.10), INTC: 33.86 (-0.17), PANW: 161.00 (+3.10), SLB: 78.16 (-0.53), DLPH: 83.19 (+3.15), VG: 6.07 (+0.03), PBY: 15.04 (+0.07), NVAX: 6.75 (-0.13), TGT: 77.18 (+0.90), LOW: 73.83 (-0.04), TMUS: 37.89 (+0.41), RAX: 25.85 (-0.22), AVT: 45.43 (+0.62), FB: 101.97 (-2.91), WFC: 54.14 (-0.95), NXPI: 78.35 (+5.35), BA: 148.07 (+0.89), CELG: 122.71 (-2.22), BWA: 42.82 (+1.25), AA: 8.93 (-0.02), IRWD: 11.36 (+0.16), GILD: 108.13 (-1.08), TXN: 56.72 (+0.15), CVS: 98.78 (-5.02), MCD: 112.25 (-0.37), IDXX: 68.62 (-1.34), PAY: 30.14 (+0.02), CVX: 90.88 (+0.99), SHW: 266.83 (+8.72), BRK.B: 136.02 (-1.87), WTW: 15.38 (-0.37), GE: 28.92 (-0.42), LMT: 219.83 (+1.58), F: 14.81 (+0.08), WWD: 45.50 (-0.49), BWLD: 154.27 (+1.82), SBUX: 62.57 (+0.07), T: 33.51 (-0.04), ETP: 44.16 (+0.15), V: 77.58 (-0.93), DPZ: 106.67 (-2.73), AAPL: 119.50 (-1.03), SWIR: 24.92 (-0.54), AMZN: 625.90 (-0.65), CX: 6.31 (-0.17), HD: 123.64 (+0.01), ORLY: 276.26 (+0.31), DIS: 113.74 (-1.30), DIN: 83.45 (-1.40), DRI: 61.89 (-0.54), NFLX: 108.38 (+3.26), GM: 34.91 (+0.16), VZ: 46.88 (+0.48), FTNT: 34.36 (+0.30), WING: 23.13 (-1.26)
Will AbbVie (ABBV) Surprise on Earnings Again in Q3?
Arpita Dutt - Zacks Investment Research - Thu Oct 29, 3:31PM CDT
Focus on AbbVie's (ABBV) third quarter call will be on the performance of key drugs - Humira, Viekira Pak and Imbruvica.
JNJ: 101.03 (-0.34), ESRX: 86.38 (-0.77), GILD: 108.13 (-1.08), SRPT: 24.06 (-0.57), ABBV: 59.55 (+5.45)
Gilead Sciences (GILD) Crosses Pivot Point Resistance at $109.58
Comtex SmarTrend(R) - Thu Oct 29, 10:50AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) have bullishly opened above the pivot of $107.76 today and have reached the first resistance level of $109.58. Analysts will be watching for a cross of the next upside pivot targets of $111.03 and $114.30.
GILD: 108.13 (-1.08)
T-Cell Immunotherapy Market Report, 2015-2030 - Key Players, Development Stage of Pipeline Products and Targeted Indications
M2 - Thu Oct 29, 10:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/559s4b/tcell) has announced the addition of the "T-Cell Immunotherapy Market, 2015-2030" report to their offering. This report provides an extensive study of the field of T-cell immunotherapy. With no marketed products, this emerging field is still in its infancy; the report provides a comprehensive view of the market segmented into the following three sub-groups: CAR-T therapies, TCR therapies and TIL therapies. The market is characterised by a robust and opportunistic pipeline of products targeting both haematological cancers and solid tumours. As mentioned earlier, several research institutes have played a critical role in progression of the technology to its current stage. Post the initial research, industry players have collaborated with non-industry participants to fund the clinical and commercial development of these products. Some late stage products that have emerged out of such collaborations include CTL-019 (Novartis/University of Pennsylvania / The Children's Hospital of Philadelphia), JCAR017 (Juno Therapeutics / Seattle Children's Hospital), KTE-C19 and NY-ESO-1 TCR (Kite Pharma / National Cancer Institute), CD19-CAR (Takara Bio / Jichi Medical University) and LN-144 (Lion Biotechnologies / National Cancer Institute). Encouraging clinical results have accelerated the progress of these therapies as they have emerged as one of the most effective ways of leveraging the potential of immune system. The market is also seeing a growing interest from several technology providers, especially those with capabilities in genome editing and viral and non-viral gene transfer. In addition, several T-cell immunotherapy companies and technology providers are also developing innovative safety switches to manage known side effects such as cytokine release syndrome and B-cell aplasia. One of the key objectives of the study is to review and quantify the opportunities laid by the innovative programs of both small and big pharma firms. The unexploited and promising nature of this market supports the hopes pinned on multiple start-ups by several strategic investors and venture capital firms. Amongst other elements, the report elaborates on the following key areas: - The current state of the market with respect to key players, development stage of pipeline products (both clinical / preclinical) and targeted indications - Partnerships which have taken place in the recent past covering research and development collaborations, manufacturing agreements, license agreements specific to technology platforms, product co-development and co-commercialisation - Innovative technological platforms, such as safety switches, which have contributed significantly in overcoming the existing gaps in therapy regimen - Various investments and grants received by the companies focused in this area - Therapeutic areas forming the current focus of developers, the gradual drift and opportunity offered by non-oncological therapeutic areas - Competitive landscape, challenges and expected trend of market evolution within the three sub-segments - Development and sales potential based on target consumer segments, likely adoption rate and expected pricing The research, analysis and insights presented in this report include potential sales of several CAR-T therapies, TCR therapies and TIL therapies; this analysis is backed by a deep understanding of key drivers behind the growth. With most products still in the early stage of development, we have provided three market forecast scenarios to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of industry evolution. All actual figures have been sourced and analysed from publicly available information. The figures mentioned in this report are in USD, unless otherwise specified. Companies Mentioned - Partial List of the 250 Companies - Cellular Therapeutics - Celyad - Children with Leukaemia - Chinese PLA General Hospital - City of Hope Medical Center - CLL Global Research Foundation Alliance - Cold Genesys - Conkwest - Cowen Investment - CRISPR Therapeutics - Fujita Health University - GammaCell Biotechnologies - Genentech - Gilead Sciences - GlaxoSmithKline - Google Ventures - Griffin Securities - H. Lee Moffitt Cancer Center and Research Institute - MaxCyte - Mayo Clinic - Medigene - MolMed - Monash University - Morphotek - Mustang Therapeutics - Nagoya University - Nantes University Hospital - Nantworks - National Cancer Institute - National Institute of Health - Peking University - Perceptive Advisors - Peter MacCallum Cancer Centre, University of Melbourne - Quogue Capital - QVT Financial For more information visit http://www.researchandmarkets.com/research/559s4b/tcell
KITE: 68.05 (-0.72), GILD: 108.13 (-1.08), LBIO: 6.47 (-0.14), JUNO: 51.76 (+0.37), GSK: 43.06 (+0.27), NVS: 90.43 (-0.53), CYAD: 37.34 (-1.09)
Another Strong Quarter for Gilead Sciences, Inc.
Keith Speights, The Motley Fool - Motley Fool - Thu Oct 29, 7:02AM CDT
Image Source: Gilead Sciences Gilead Sciences exceeded expectations when it reported financial results three months ago. Some big questions loomed large, though, as the biotech wrapped up its third quarter. Those questions centered on how well...
GILD: 108.13 (-1.08), MRK: 54.66 (-0.21), ABBV: 59.55 (+5.45)
Gilead submits NDA to US FDA for once daily fixed-dose combination of sofosbuvir/velpatasvir for treating six genotypes of hepatitis C
M2 - Thu Oct 29, 5:42AM CDT
Biopharmaceutical company Gilead Sciences (Nasdaq:GILD) reported on Wednesday that it has submitted a New Drug Application (NDA) for an investigational, once-daily fixed-dose combination of the nucleotide analog polymerase inhibitor sofosbuvir (SOF) and velpatasvir (VEL) for chronic genotype 1-6 hepatitis C virus (HCV) infection.
GILD: 108.13 (-1.08)
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Sofosbuvir/Velpatasvir for Treatment of All Six Genotypes of Hepatitis C
Business Wire - Wed Oct 28, 4:52PM CDT
-- Filing is Company's Third in Three Years for a New HCV Medicine --
GILD: 108.13 (-1.08)
Stocks Twist and Turn With Fed's Muddled Outlook
at The Street - Wed Oct 28, 3:02PM CDT
The Federal Reserve could raise rates this year. It could raise them next year. The question of 'when' weighed heavy on Wall Street Wednesday.
ANTM: 139.15 (-2.19), RDS.A: 52.46 (-0.10), GILD: 108.13 (-1.08), XOM: 82.74 (+0.51), BP: 35.70 (-0.01), TWTR: 28.46 (-0.60), CVX: 90.88 (+0.99), AAPL: 119.50 (-1.03), SLB: 78.16 (-0.53), XLE: 68.03 (+0.44)
Pyramiding Into A Stock Helps Minimize Buying Risk
at Investor's Business Daily - Wed Oct 28, 2:34PM CDT
Going "all in" can pay off big time in poker. But when it comes to investing, the savvy trader knows that jumping into a stock all at once can be highly risky. If the stock takes off like a rocket, that's great. If it heads south instead, you could...
GILD: 108.13 (-1.08)
Stocks Trim Gains After Fed Leaves December Hike in Play
at The Street - Wed Oct 28, 1:54PM CDT
Stocks retreat from session highs, and briefly dipped into the red, on Wednesday after the Federal Reserve held rates steady but left a potential December rate hike in play.
HSY: 88.69 (-0.27), XOM: 82.74 (+0.51), H: 50.40 (+0.10), SLB: 78.16 (-0.53), HOT: 79.87 (+0.99), RAD: 7.88 (unch), ANTM: 139.15 (-2.19), WBA: 84.68 (+0.80), RDS.A: 52.46 (-0.10), GILD: 108.13 (-1.08), BP: 35.70 (-0.01), AIG: 63.06 (-0.43), CVX: 90.88 (+0.99), TWTR: 28.46 (-0.60), AAPL: 119.50 (-1.03), XLE: 68.03 (+0.44)
Research and Markets: Global HIV Drugs Market 2015-2019 - Key Vendors are Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson & Merck
Business Wire - Wed Oct 28, 12:54PM CDT
Research and Markets (http://www.researchandmarkets.com/research/hck7vp/global_hiv_drugs) has announced the addition of the "Global HIV Drugs Market 2015-2019" report to their offering.
JNJ: 101.03 (-0.34), GILD: 108.13 (-1.08), MRK: 54.66 (-0.21), GSK: 43.06 (+0.27)
Intercept Pharma NASH Drug Disappoints In Japan
at Investor's Business Daily - Wed Oct 28, 11:05AM CDT
Biotech Intercept Pharmaceuticals (ICPT) was trading down sharply Wednesday morning after the first Japanese trial of its fatty-liver-disease drug produced mixed results. The midstage trial, conducted by Intercept's Japanese partner Dainippon...
GILD: 108.13 (-1.08), ICPT: 157.20 (-7.75)
Stocks Up as Energy Climbs on Rise in Crude Inventories
at The Street - Wed Oct 28, 10:12AM CDT
Stocks extend gains on Wednesday as the energy sector rallies on a better-than-expected read on crude inventories.
HSY: 88.69 (-0.27), XOM: 82.74 (+0.51), H: 50.40 (+0.10), SLB: 78.16 (-0.53), RAD: 7.88 (unch), HOT: 79.87 (+0.99), ANTM: 139.15 (-2.19), RDS.A: 52.46 (-0.10), WBA: 84.68 (+0.80), GILD: 108.13 (-1.08), BP: 35.70 (-0.01), AIG: 63.06 (-0.43), TWTR: 28.46 (-0.60), CVX: 90.88 (+0.99), AAPL: 119.50 (-1.03), XLE: 68.03 (+0.44)
Gilead Proves Again Why It's the Best Biotech Company on the Planet
at The Street - Wed Oct 28, 9:09AM CDT
Gilead's hepatitis C drugs are probably the best example of the innovation in medicine we want the biotech industry to strive for when developing new products.
ESRX: 86.38 (-0.77), GILD: 108.13 (-1.08), PFE: 33.82 (-0.95), MRK: 54.66 (-0.21), ABBV: 59.55 (+5.45), GSK: 43.06 (+0.27)
Biotech Stock Roundup: Biogen Tops Estimates, FDA Approves Alexion's Strensiq
Arpita Dutt - Zacks Investment Research - Wed Oct 28, 8:57AM CDT
While companies like Biogen and Gilead have reported third quarter results, other major biotechs like Amgen and Vertex will be reporting this week.
BIIB: 290.51 (-3.21), VRTX: 124.74 (-1.43), GILD: 108.13 (-1.08), RPRX: 1.71 (-0.37), AMGN: 158.18 (-2.40), ABBV: 59.55 (+5.45), SPPI: 5.21 (+0.10)
Gilead (GILD) Beats on Q3 Earnings, HCV Drugs Lose Shine
Zacks Equity Research - Zacks Investment Research - Wed Oct 28, 8:26AM CDT
Gilead Sciences, Inc.'s (GILD) third-quarter earnings (including stock-based compensation expenses) of $3.19 per share.
GILD: 108.13 (-1.08), MRK: 54.66 (-0.21), ABBV: 59.55 (+5.45), ANIK: 38.52 (-0.55)
This Company's 31-Year Adjusted EPS Growth Streak Will Likely End in 2015
Sean Williams, The Motley Fool - Motley Fool - Wed Oct 28, 8:02AM CDT
Image source: Federal Reserve Bank of New York. Look around the stock market and you'll probably struggle to find a company that's been able to grow its adjusted earnings per share for 10 consecutive years. It's tough because many companies are...
JNJ: 101.03 (-0.34), GILD: 108.13 (-1.08)
Gilead Sciences (GILD) Earnings Report: Q3 2015 Conference Call Transcript
at The Street - Wed Oct 28, 7:58AM CDT
The following Gilead Sciences (GILD) conference call took place on October 27, 2015, 04:30 PM ET. This is a transcript of that earnings call:
GILD: 108.13 (-1.08)
Gilead Sciences Is Shrugging Off Its Competitors
Todd Campbell, The Motley Fool - Motley Fool - Sat Oct 31, 6:20AM CDT
Image source: Gilead Sciences. The fact that Gilead Sciences shares have toppled by 8% since July might have you thinking that competitors have the company on the ropes, but Gilead Sciences' third-quarter results show investors that simply isn't...
GILD: 108.13 (-1.08), MRK: 54.66 (-0.21), ABBV: 59.55 (+5.45)
Gilead Sciences and WuXi PharmaTech Announce Collaboration for a Dedicated Analytical and Stability Testing Facility
PR Newswire - Thu Oct 29, 9:00PM CDT
Gilead Sciences, Inc., and WuXi PharmaTech (Cayman) Inc. (NYSE: WX), today announced that they have entered into a strategic partnership to conduct analytical and stability studies of small-molecule new chemical entities to support global marketing applications and commercial products.
GILD: 108.13 (-1.08), WX: 44.70 (+0.10)
Jim Cramer's 'Mad Money' Recap: Using What Went Wrong to Find Buying Opportunities
at The Street - Thu Oct 29, 7:16PM CDT
One company's awful earnings can drag others down in the sector, making bargains for the taking, Cramer syas.
HON: 103.28 (+0.34), PYPL: 36.01 (+0.10), INTC: 33.86 (-0.17), PANW: 161.00 (+3.10), SLB: 78.16 (-0.53), DLPH: 83.19 (+3.15), VG: 6.07 (+0.03), PBY: 15.04 (+0.07), NVAX: 6.75 (-0.13), TGT: 77.18 (+0.90), LOW: 73.83 (-0.04), TMUS: 37.89 (+0.41), RAX: 25.85 (-0.22), AVT: 45.43 (+0.62), FB: 101.97 (-2.91), WFC: 54.14 (-0.95), NXPI: 78.35 (+5.35), BA: 148.07 (+0.89), CELG: 122.71 (-2.22), BWA: 42.82 (+1.25), AA: 8.93 (-0.02), IRWD: 11.36 (+0.16), GILD: 108.13 (-1.08), TXN: 56.72 (+0.15), CVS: 98.78 (-5.02), MCD: 112.25 (-0.37), IDXX: 68.62 (-1.34), PAY: 30.14 (+0.02), CVX: 90.88 (+0.99), SHW: 266.83 (+8.72), BRK.B: 136.02 (-1.87), WTW: 15.38 (-0.37), GE: 28.92 (-0.42), LMT: 219.83 (+1.58), F: 14.81 (+0.08), WWD: 45.50 (-0.49), BWLD: 154.27 (+1.82), SBUX: 62.57 (+0.07), T: 33.51 (-0.04), ETP: 44.16 (+0.15), V: 77.58 (-0.93), DPZ: 106.67 (-2.73), AAPL: 119.50 (-1.03), SWIR: 24.92 (-0.54), AMZN: 625.90 (-0.65), CX: 6.31 (-0.17), HD: 123.64 (+0.01), ORLY: 276.26 (+0.31), DIS: 113.74 (-1.30), DIN: 83.45 (-1.40), DRI: 61.89 (-0.54), NFLX: 108.38 (+3.26), GM: 34.91 (+0.16), VZ: 46.88 (+0.48), FTNT: 34.36 (+0.30), WING: 23.13 (-1.26)
Will AbbVie (ABBV) Surprise on Earnings Again in Q3?
Arpita Dutt - Zacks Investment Research - Thu Oct 29, 3:31PM CDT
Focus on AbbVie's (ABBV) third quarter call will be on the performance of key drugs - Humira, Viekira Pak and Imbruvica.
JNJ: 101.03 (-0.34), ESRX: 86.38 (-0.77), GILD: 108.13 (-1.08), SRPT: 24.06 (-0.57), ABBV: 59.55 (+5.45)
Gilead Sciences (GILD) Crosses Pivot Point Resistance at $109.58
Comtex SmarTrend(R) - Thu Oct 29, 10:50AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) have bullishly opened above the pivot of $107.76 today and have reached the first resistance level of $109.58. Analysts will be watching for a cross of the next upside pivot targets of $111.03 and $114.30.
GILD: 108.13 (-1.08)
T-Cell Immunotherapy Market Report, 2015-2030 - Key Players, Development Stage of Pipeline Products and Targeted Indications
M2 - Thu Oct 29, 10:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/559s4b/tcell) has announced the addition of the "T-Cell Immunotherapy Market, 2015-2030" report to their offering. This report provides an extensive study of the field of T-cell immunotherapy. With no marketed products, this emerging field is still in its infancy; the report provides a comprehensive view of the market segmented into the following three sub-groups: CAR-T therapies, TCR therapies and TIL therapies. The market is characterised by a robust and opportunistic pipeline of products targeting both haematological cancers and solid tumours. As mentioned earlier, several research institutes have played a critical role in progression of the technology to its current stage. Post the initial research, industry players have collaborated with non-industry participants to fund the clinical and commercial development of these products. Some late stage products that have emerged out of such collaborations include CTL-019 (Novartis/University of Pennsylvania / The Children's Hospital of Philadelphia), JCAR017 (Juno Therapeutics / Seattle Children's Hospital), KTE-C19 and NY-ESO-1 TCR (Kite Pharma / National Cancer Institute), CD19-CAR (Takara Bio / Jichi Medical University) and LN-144 (Lion Biotechnologies / National Cancer Institute). Encouraging clinical results have accelerated the progress of these therapies as they have emerged as one of the most effective ways of leveraging the potential of immune system. The market is also seeing a growing interest from several technology providers, especially those with capabilities in genome editing and viral and non-viral gene transfer. In addition, several T-cell immunotherapy companies and technology providers are also developing innovative safety switches to manage known side effects such as cytokine release syndrome and B-cell aplasia. One of the key objectives of the study is to review and quantify the opportunities laid by the innovative programs of both small and big pharma firms. The unexploited and promising nature of this market supports the hopes pinned on multiple start-ups by several strategic investors and venture capital firms. Amongst other elements, the report elaborates on the following key areas: - The current state of the market with respect to key players, development stage of pipeline products (both clinical / preclinical) and targeted indications - Partnerships which have taken place in the recent past covering research and development collaborations, manufacturing agreements, license agreements specific to technology platforms, product co-development and co-commercialisation - Innovative technological platforms, such as safety switches, which have contributed significantly in overcoming the existing gaps in therapy regimen - Various investments and grants received by the companies focused in this area - Therapeutic areas forming the current focus of developers, the gradual drift and opportunity offered by non-oncological therapeutic areas - Competitive landscape, challenges and expected trend of market evolution within the three sub-segments - Development and sales potential based on target consumer segments, likely adoption rate and expected pricing The research, analysis and insights presented in this report include potential sales of several CAR-T therapies, TCR therapies and TIL therapies; this analysis is backed by a deep understanding of key drivers behind the growth. With most products still in the early stage of development, we have provided three market forecast scenarios to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of industry evolution. All actual figures have been sourced and analysed from publicly available information. The figures mentioned in this report are in USD, unless otherwise specified. Companies Mentioned - Partial List of the 250 Companies - Cellular Therapeutics - Celyad - Children with Leukaemia - Chinese PLA General Hospital - City of Hope Medical Center - CLL Global Research Foundation Alliance - Cold Genesys - Conkwest - Cowen Investment - CRISPR Therapeutics - Fujita Health University - GammaCell Biotechnologies - Genentech - Gilead Sciences - GlaxoSmithKline - Google Ventures - Griffin Securities - H. Lee Moffitt Cancer Center and Research Institute - MaxCyte - Mayo Clinic - Medigene - MolMed - Monash University - Morphotek - Mustang Therapeutics - Nagoya University - Nantes University Hospital - Nantworks - National Cancer Institute - National Institute of Health - Peking University - Perceptive Advisors - Peter MacCallum Cancer Centre, University of Melbourne - Quogue Capital - QVT Financial For more information visit http://www.researchandmarkets.com/research/559s4b/tcell
KITE: 68.05 (-0.72), GILD: 108.13 (-1.08), LBIO: 6.47 (-0.14), JUNO: 51.76 (+0.37), GSK: 43.06 (+0.27), NVS: 90.43 (-0.53), CYAD: 37.34 (-1.09)
Another Strong Quarter for Gilead Sciences, Inc.
Keith Speights, The Motley Fool - Motley Fool - Thu Oct 29, 7:02AM CDT
Image Source: Gilead Sciences Gilead Sciences exceeded expectations when it reported financial results three months ago. Some big questions loomed large, though, as the biotech wrapped up its third quarter. Those questions centered on how well...
GILD: 108.13 (-1.08), MRK: 54.66 (-0.21), ABBV: 59.55 (+5.45)
Gilead submits NDA to US FDA for once daily fixed-dose combination of sofosbuvir/velpatasvir for treating six genotypes of hepatitis C
M2 - Thu Oct 29, 5:42AM CDT
Biopharmaceutical company Gilead Sciences (Nasdaq:GILD) reported on Wednesday that it has submitted a New Drug Application (NDA) for an investigational, once-daily fixed-dose combination of the nucleotide analog polymerase inhibitor sofosbuvir (SOF) and velpatasvir (VEL) for chronic genotype 1-6 hepatitis C virus (HCV) infection.
GILD: 108.13 (-1.08)
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Sofosbuvir/Velpatasvir for Treatment of All Six Genotypes of Hepatitis C
Business Wire - Wed Oct 28, 4:52PM CDT
-- Filing is Company's Third in Three Years for a New HCV Medicine --
GILD: 108.13 (-1.08)
Stocks Twist and Turn With Fed's Muddled Outlook
at The Street - Wed Oct 28, 3:02PM CDT
The Federal Reserve could raise rates this year. It could raise them next year. The question of 'when' weighed heavy on Wall Street Wednesday.
ANTM: 139.15 (-2.19), RDS.A: 52.46 (-0.10), GILD: 108.13 (-1.08), XOM: 82.74 (+0.51), BP: 35.70 (-0.01), TWTR: 28.46 (-0.60), CVX: 90.88 (+0.99), AAPL: 119.50 (-1.03), SLB: 78.16 (-0.53), XLE: 68.03 (+0.44)
Pyramiding Into A Stock Helps Minimize Buying Risk
at Investor's Business Daily - Wed Oct 28, 2:34PM CDT
Going "all in" can pay off big time in poker. But when it comes to investing, the savvy trader knows that jumping into a stock all at once can be highly risky. If the stock takes off like a rocket, that's great. If it heads south instead, you could...
GILD: 108.13 (-1.08)
Stocks Trim Gains After Fed Leaves December Hike in Play
at The Street - Wed Oct 28, 1:54PM CDT
Stocks retreat from session highs, and briefly dipped into the red, on Wednesday after the Federal Reserve held rates steady but left a potential December rate hike in play.
HSY: 88.69 (-0.27), XOM: 82.74 (+0.51), H: 50.40 (+0.10), SLB: 78.16 (-0.53), HOT: 79.87 (+0.99), RAD: 7.88 (unch), ANTM: 139.15 (-2.19), WBA: 84.68 (+0.80), RDS.A: 52.46 (-0.10), GILD: 108.13 (-1.08), BP: 35.70 (-0.01), AIG: 63.06 (-0.43), CVX: 90.88 (+0.99), TWTR: 28.46 (-0.60), AAPL: 119.50 (-1.03), XLE: 68.03 (+0.44)
Research and Markets: Global HIV Drugs Market 2015-2019 - Key Vendors are Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson & Merck
Business Wire - Wed Oct 28, 12:54PM CDT
Research and Markets (http://www.researchandmarkets.com/research/hck7vp/global_hiv_drugs) has announced the addition of the "Global HIV Drugs Market 2015-2019" report to their offering.
JNJ: 101.03 (-0.34), GILD: 108.13 (-1.08), MRK: 54.66 (-0.21), GSK: 43.06 (+0.27)
Intercept Pharma NASH Drug Disappoints In Japan
at Investor's Business Daily - Wed Oct 28, 11:05AM CDT
Biotech Intercept Pharmaceuticals (ICPT) was trading down sharply Wednesday morning after the first Japanese trial of its fatty-liver-disease drug produced mixed results. The midstage trial, conducted by Intercept's Japanese partner Dainippon...
GILD: 108.13 (-1.08), ICPT: 157.20 (-7.75)
Stocks Up as Energy Climbs on Rise in Crude Inventories
at The Street - Wed Oct 28, 10:12AM CDT
Stocks extend gains on Wednesday as the energy sector rallies on a better-than-expected read on crude inventories.
HSY: 88.69 (-0.27), XOM: 82.74 (+0.51), H: 50.40 (+0.10), SLB: 78.16 (-0.53), RAD: 7.88 (unch), HOT: 79.87 (+0.99), ANTM: 139.15 (-2.19), RDS.A: 52.46 (-0.10), WBA: 84.68 (+0.80), GILD: 108.13 (-1.08), BP: 35.70 (-0.01), AIG: 63.06 (-0.43), TWTR: 28.46 (-0.60), CVX: 90.88 (+0.99), AAPL: 119.50 (-1.03), XLE: 68.03 (+0.44)
Gilead Proves Again Why It's the Best Biotech Company on the Planet
at The Street - Wed Oct 28, 9:09AM CDT
Gilead's hepatitis C drugs are probably the best example of the innovation in medicine we want the biotech industry to strive for when developing new products.
ESRX: 86.38 (-0.77), GILD: 108.13 (-1.08), PFE: 33.82 (-0.95), MRK: 54.66 (-0.21), ABBV: 59.55 (+5.45), GSK: 43.06 (+0.27)
Biotech Stock Roundup: Biogen Tops Estimates, FDA Approves Alexion's Strensiq
Arpita Dutt - Zacks Investment Research - Wed Oct 28, 8:57AM CDT
While companies like Biogen and Gilead have reported third quarter results, other major biotechs like Amgen and Vertex will be reporting this week.
BIIB: 290.51 (-3.21), VRTX: 124.74 (-1.43), GILD: 108.13 (-1.08), RPRX: 1.71 (-0.37), AMGN: 158.18 (-2.40), ABBV: 59.55 (+5.45), SPPI: 5.21 (+0.10)
Gilead (GILD) Beats on Q3 Earnings, HCV Drugs Lose Shine
Zacks Equity Research - Zacks Investment Research - Wed Oct 28, 8:26AM CDT
Gilead Sciences, Inc.'s (GILD) third-quarter earnings (including stock-based compensation expenses) of $3.19 per share.
GILD: 108.13 (-1.08), MRK: 54.66 (-0.21), ABBV: 59.55 (+5.45), ANIK: 38.52 (-0.55)
This Company's 31-Year Adjusted EPS Growth Streak Will Likely End in 2015
Sean Williams, The Motley Fool - Motley Fool - Wed Oct 28, 8:02AM CDT
Image source: Federal Reserve Bank of New York. Look around the stock market and you'll probably struggle to find a company that's been able to grow its adjusted earnings per share for 10 consecutive years. It's tough because many companies are...
JNJ: 101.03 (-0.34), GILD: 108.13 (-1.08)
Gilead Sciences (GILD) Earnings Report: Q3 2015 Conference Call Transcript
at The Street - Wed Oct 28, 7:58AM CDT
The following Gilead Sciences (GILD) conference call took place on October 27, 2015, 04:30 PM ET. This is a transcript of that earnings call:
GILD: 108.13 (-1.08)
